OBJECTIVE: Major depressive disorder is the most common psychiatric disorder, worldwide, yet response and remission rates are still unsatisfactory. The identification of genetic predictors of antidepressant (AD) response could provide a promising opportunity to improve current AD efficacy through the personalization of treatment. The major steps and findings along this path are reviewed together with their clinical implications and limitations. METHOD: We systematically reviewed the literature through MEDLINE and Embase database searches, using any word combination of "antidepressant," "gene," "polymorphism," "pharmacogenetics," "genome-wide association study," "GWAS," "response," and "adverse drug reactions." Experimental works and reviews published until March 2012 were collected and compared. RESULTS: Numerous genes pertaining to several functional systems were associated with AD response. The more robust findings were found for the following genes: solute carrier family 6 (neurotransmitter transporter), member 4; serotonin receptor 1A and 2A; brain-derived neurotrophic factor; and catechol-O-methyltransferase. Genome-wide association studies (GWASs) provided many top markers, even if none of them reached genome-wide significance. CONCLUSIONS: AD pharmacogenetics have not produced any knowledge applicable to routine clinical practice yet, as results were mainly inconsistent across studies. Despite this, the rising awareness about methodological deficits of past studies could allow for the identication of more suitable strategies, such as the integration of the GWAS approach with the candidate gene approach, and innovative methodologies, such as pathway analysis and study of depressive endophenotypes.
OBJECTIVE: Major depressive disorder is the most common psychiatric disorder, worldwide, yet response and remission rates are still unsatisfactory. The identification of genetic predictors of antidepressant (AD) response could provide a promising opportunity to improve current AD efficacy through the personalization of treatment. The major steps and findings along this path are reviewed together with their clinical implications and limitations. METHOD: We systematically reviewed the literature through MEDLINE and Embase database searches, using any word combination of "antidepressant," "gene," "polymorphism," "pharmacogenetics," "genome-wide association study," "GWAS," "response," and "adverse drug reactions." Experimental works and reviews published until March 2012 were collected and compared. RESULTS: Numerous genes pertaining to several functional systems were associated with AD response. The more robust findings were found for the following genes: solute carrier family 6 (neurotransmitter transporter), member 4; serotonin receptor 1A and 2A; brain-derived neurotrophic factor; and catechol-O-methyltransferase. Genome-wide association studies (GWASs) provided many top markers, even if none of them reached genome-wide significance. CONCLUSIONS: AD pharmacogenetics have not produced any knowledge applicable to routine clinical practice yet, as results were mainly inconsistent across studies. Despite this, the rising awareness about methodological deficits of past studies could allow for the identication of more suitable strategies, such as the integration of the GWAS approach with the candidate gene approach, and innovative methodologies, such as pathway analysis and study of depressive endophenotypes.
Authors: Daniel J Müller; T G Schulze; F Macciardi; S Ohlraun; M M Gross; H Scherk; H Neidt; Y V Syagailo; M Grässle; M M Nöthen; W Maier; K-P Lesch; M Rietschel Journal: Pharmacopsychiatry Date: 2002-07 Impact factor: 5.788
Authors: Stacey A Sakowski; Timothy J Geddes; David M Thomas; Edi Levi; James S Hatfield; Donald M Kuhn Journal: Brain Res Date: 2006-04-11 Impact factor: 3.252
Authors: Merja Viikki; Olli Kampman; Ari Illi; Eija Setälä-Soikkeli; Sami Anttila; Martti Huuhka; Timo Nuolivirta; Outi Poutanen; Nina Mononen; Terho Lehtimäki; Esa Leinonen Journal: Neurosci Lett Date: 2009-10-27 Impact factor: 3.046
Authors: Francis E Lotrich; Bruce G Pollock; Margaret Kirshner; Robert F Ferrell; Charles F Reynolds Iii Journal: J Psychiatry Neurosci Date: 2008-03 Impact factor: 6.186
Authors: Magnus Lekman; Gonzalo Laje; Dennis Charney; A John Rush; Alexander F Wilson; Alexa J M Sorant; Robert Lipsky; Stephen R Wisniewski; Husseini Manji; Francis J McMahon; Silvia Paddock Journal: Biol Psychiatry Date: 2008-01-11 Impact factor: 13.382
Authors: G Spurlock; A Heils; P Holmans; J Williams; U M D'Souza; A Cardno; K C Murphy; L Jones; P R Buckland; P McGuffin; K P Lesch; M J Owen Journal: Mol Psychiatry Date: 1998-01 Impact factor: 15.992
Authors: D J Müller; E J Brandl; F Degenhardt; K Domschke; H Grabe; O Gruber; J Hebebrand; W Maier; A Menke; M Riemenschneider; M Rietschel; D Rujescu; T G Schulze; L Tebartz van Elst; O Tüscher; J Deckert Journal: Nervenarzt Date: 2018-03 Impact factor: 1.214
Authors: K Holl; H He; M Wedemeyer; L Clopton; S Wert; J K Meckes; R Cheng; A Kastner; A A Palmer; E E Redei; L C Solberg Woods Journal: Genes Brain Behav Date: 2017-09-26 Impact factor: 3.449
Authors: Bharathi S Gadad; Prithvi Raj; Manish K Jha; Thomas Carmody; Igor Dozmorov; Taryn L Mayes; Edward K Wakeland; Madhukar H Trivedi Journal: Mol Neuropsychiatry Date: 2018-05-03